All In Biotech

Drug Trial Radar · NCT05216224

ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

95

Actual

Start

Dec 29, 2021

Primary completion

Dec 23, 2022

Study completion Jan 24, 2023

Sponsor

Lead sponsor
Aclaris Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).

Conditions

  • Hidradenitis Suppurativa

Interventions

  • ATI-450Drug

    Oral, small molecule MK2 inhibitor

  • Placebo oral tabletDrug

    Placebo tablet manufactured to match ATI-450 in appearance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 12Time frame: Baseline, Week 12

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Aclaris Investigational Site

    Birmingham, Alabama

  • Aclaris Investigational Site

    Fort Smith, Arkansas

  • Aclaris Investigational Site

    Encino, California

  • Aclaris Investigational Site

    San Francisco, California

  • Aclaris Investigational Site

    Thousand Oaks, California

  • Aclaris Investigational Site

    Boca Raton, Florida

  • Aclaris Investigational Site

    Hollywood, Florida

  • Aclaris Investigational Site

    Tampa, Florida

  • Aclaris Investigational Site

    Marietta, Georgia

  • Aclaris Investigational Site

    Sandy Springs, Georgia

  • Aclaris Investigational Site

    Metairie, Louisiana

  • Aclaris Investigational Site

    Fort Gratiot, Michigan

  • Aclaris Investigational Site

    Charlotte, North Carolina

  • Aclaris Investigational Site

    Athens, Ohio

  • Aclaris Investigational Site

    Mason, Ohio

  • Aclaris Investigational Site

    Hershey, Pennsylvania

  • Aclaris Investigational Site

    Anderson, South Carolina

  • Aclaris Investigational Site

    Nashville, Tennessee

  • Aclaris Investigational Site

    Houston, Texas

  • Aclaris Investigational Site

    Sugar Land, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.